摘要
目的探究布地奈德联合沙丁胺醇治疗哮喘-慢阻肺重叠综合征的效果及对患者血清炎症因子水平的影响。方法选取本院2019年3月至2021年3月收治的48例哮喘-慢阻肺重叠综合征患者,遵循随机数字表法将其分为参照组(n=24)和研究组(n=24)。参照组开展沙丁胺醇治疗,研究组开展布地奈德联合沙丁胺醇治疗。比较两组的治疗效果。结果研究组的治疗总有效率高于参照组(P<0.05)。治疗后,研究组的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC及6min步行距离(6MWD)优于参照组(P<0.05)。治疗后,研究组的白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平均低于参照组(P<0.05)。治疗后,研究组的呼出一氧化氮(FeNO)水平、嗜酸性粒细胞计数(EOS)及圣乔治呼吸问卷(SGRQ)评分均低于参照组(P<0.05)。结论布地奈德联合沙丁胺醇治疗哮喘-慢阻肺重叠综合征的效果显著,可改善患者的血清炎症因子水平、肺功能、生活质量及FeNO水平、EOS。
Objective To investigate the effect of budesonide combined with salbutamol in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome and its influence on the levels of serum inflammatory factors.Methods Forty-eight patients with asthma-chronic obstructive pulmonary disease overlap syndrome admitted in our hospital from March 2019 to March 2021 were selected and divided into reference group(n=24)and study group(n=24)according to random number table method.The reference group was treated with salbutamol,and the study group was treated with budesonide combined with salbutamol.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the reference group(P<0.05).After treatment,the forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC and 6 min walking distance(6MWD)in the study group were better than those in the reference group(P<0.05).After treatment,the levels of interleukin-4(IL-4),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and high sensitivity C-reactive protein(hs-CRP)in the study group were lower than those in the reference group(P<0.05).After treatment,the fractional exhale nitric oxide(FeNO)level,eosinophil counts(EOS)and St.George's Respiratory Questionnaire(SGRQ)score in the study group were lower than those in the reference group(P<0.05).Conclusion Budesonide combined with salbutamol in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome has a significant effect,which can improve the levels of serum inflammatory factors,lung function,quality of life,FeNO level and EOS of patients.
作者
杨旭旭
姜媛媛
YANG Xuxu;JIANG Yuanyuan(Respiratory and Critical Care Medicine Department,Xingyuan Hosital of Yulin,Yulin 719000,China)
出处
《临床医学研究与实践》
2023年第4期43-45,共3页
Clinical Research and Practice
关键词
布地奈德
沙丁胺醇
哮喘-慢阻肺重叠综合征
炎症因子
肺功能
budesonide
salbutamol
asthma-chronic obstructive pulmonary disease overlap syndrome
inflammatory factor
lung function
